Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Schmid, S. Noeske, A. Hattesohl, T. Greulich, R. Bals, C. Vogelmeier, A. R. Koczulla (Germany). The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients. Eur Respir J 2010; 36: Suppl. 54, 2346

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease. Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of clinical worsening in refractory pulmonary hypertension in children Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation Source: Eur Respir J 2014; 43: 1306-1315 Year: 2014 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Respiratory function and airway inflammation in patients with hypothyroidism. The effect of treatment Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 The link between systemic inflammation and pulmonary hypertension in patients with stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 53s Year: 2005 Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 The role of systemic markers of inflammation in bronchiectasis. Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019